RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus–host interactions and immunity contribute to the lack of biological countermeasures. This review updates the current understanding of RSV immunity and immunopathology with a focus on interferon responses, animal modeling, and correlates of protection.
显示更多 [+] 显示较少 [-]AGROVOC关键词
书目信息
出版者
Elsevier Ltd
其它主题
Therapeutics; Respiratory tract diseases
语言
英语
类型
Journal Article; Text
2024-02-29
2026-02-03
MODS